The Best of EAU15: Urothelial Cancers
The Best of EAU15: Urothelial Cancers

The Best of EAU15: Urothelial Cancers
The Best of EAU15 continues to bring you highlights from our Annual Congress. This week, we present the best that EAU15 has to offer on urothelial cancers, as selected by experts in the field. Please enjoy this selection of free previews from the EAU15 Resource Centre!
Point-counterpoint: BCG alone - still the gold standard?
Yes: Amongst other points, Prof. Maximilian Burger points out that in non-muscle invasive high-risk bladder cancer BCG remains the sole form of treatment other than early cystectomy with solid evidence.
No: Dr. Kay Thomas contends that, while BCG is a great success story for urology, BCG alone is inadequate.



Molecular profiling in bladder cancer - The Cancer Genome Atlas (TCGA) project
Dr. Seth Lerner shares the latest data from the TCGA project, reviews key translatable findings and asks if urology is ready for personalized genomic therapy.

Extended lymph node dissection in bladder cancer – What is the evidence?
Prof. Jürgen Erich Gschwend presents the available information from published retrospective and prospective studies on extended versus limited lymph node dissection during radical cystectomy in bladder cancer.
Other presentations on urothelial cancer

Is robotic cystectomy the future standard? - Yes
Prof. Peter Wiklund

State-of-the-art lecture:

Immunotherapy - Bladder cancer
Dr. Thomas Powles

State-of-the-art lecture:

When BCG fails
Prof. John Kelly

More on Urothelial Cancer

If you attended EAU15, you can access all content when you log in with the barcode on your Congress Badge. For those who couldn't join us in Madrid, you can buy access to the EAU15 Resource Centre.

For €49 (EAU Members) or €89 (non-Members) you can review over 4,000 items of scientific content, ranging from webcasts, (e-)posters and abstracts to videos and presentations. Once you select an item, you will be prompted to log in and, if necessary, purchase access.